Log in
NYSE:GMED

Globus Medical Competitors

$58.47
+0.64 (+1.11 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$57.53
Now: $58.47
$59.73
50-Day Range
$48.89
MA: $54.38
$58.06
52-Week Range
$33.41
Now: $58.47
$60.15
Volume787,508 shs
Average Volume887,801 shs
Market Capitalization$5.77 billion
P/E Ratio63.55
Dividend YieldN/A
Beta0.95

Competitors

Globus Medical (NYSE:GMED) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying GMED stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Globus Medical, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk and Volatility

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Institutional and Insider Ownership

63.9% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 66.6% of Globus Medical shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 25.6% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Abbott Laboratories and Globus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Globus Medical$785.37 million7.35$155.21 million$1.6834.80

Abbott Laboratories has higher revenue and earnings than Globus Medical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Globus Medical12.36%9.85%9.04%

Analyst Recommendations

This is a breakdown of current recommendations for Abbott Laboratories and Globus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Globus Medical041002.71

Abbott Laboratories presently has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Globus Medical has a consensus price target of $60.2857, suggesting a potential upside of 3.11%. Given Abbott Laboratories' higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Globus Medical.

Summary

Globus Medical beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Earnings & Valuation

This table compares Medtronic and Globus Medical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Globus Medical$785.37 million7.35$155.21 million$1.6834.80

Medtronic has higher revenue and earnings than Globus Medical. Medtronic is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Medtronic has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Medtronic and Globus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Globus Medical12.36%9.85%9.04%

Analyst Recommendations

This is a breakdown of current recommendations for Medtronic and Globus Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Globus Medical041002.71

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Globus Medical has a consensus price target of $60.2857, suggesting a potential upside of 3.11%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Globus Medical.

Institutional and Insider Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 66.6% of Globus Medical shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 25.6% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats Globus Medical on 10 of the 15 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Stryker (NYSE:SYK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Globus Medical and Stryker's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$785.37 million7.35$155.21 million$1.6834.80
Stryker$14.88 billion5.88$2.08 billion$8.2628.21

Stryker has higher revenue and earnings than Globus Medical. Stryker is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Globus Medical12.36%9.85%9.04%
Stryker11.38%20.53%8.89%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Stryker, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Globus Medical041002.71
Stryker291512.56

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Stryker has a consensus target price of $221.44, suggesting a potential downside of 4.97%. Given Globus Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than Stryker.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Globus Medical beats Stryker on 8 of the 15 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Globus Medical and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$785.37 million7.35$155.21 million$1.6834.80
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Intuitive Surgical has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Globus Medical12.36%9.85%9.04%
Intuitive Surgical24.45%12.08%10.44%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Globus Medical041002.71
Intuitive Surgical371202.41

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Intuitive Surgical has a consensus target price of $718.2778, suggesting a potential downside of 0.11%. Given Globus Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than Intuitive Surgical.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Intuitive Surgical beats Globus Medical on 11 of the 14 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Globus Medical and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$785.37 million7.35$155.21 million$1.6834.80
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Globus Medical. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Globus Medical12.36%9.85%9.04%
Becton, Dickinson and5.11%13.30%5.60%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Globus Medical041002.71
Becton, Dickinson and07712.60

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher possible upside, analysts clearly believe Becton, Dickinson and is more favorable than Globus Medical.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Becton, Dickinson and beats Globus Medical on 8 of the 15 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Globus Medical041002.71
Edwards Lifesciences251302.55

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Edwards Lifesciences has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Globus Medical.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Globus Medical and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$785.37 million7.35$155.21 million$1.6834.80
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Globus Medical12.36%9.85%9.04%
Edwards Lifesciences18.18%29.00%18.10%

Summary

Edwards Lifesciences beats Globus Medical on 11 of the 14 factors compared between the two stocks.


Globus Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.